What Is GLP-1 and Why Does It Matter?

Glucagon-like peptide-1 (GLP-1) is an incretin hormone naturally released by L-cells in the small intestine within minutes of eating. Its primary biological roles include stimulating insulin release from the pancreas, suppressing glucagon secretion (which reduces blood sugar), slowing the rate at which food leaves the stomach, and sending satiety signals to appetite centers in the brain. In healthy individuals, GLP-1 is broken down rapidly by the enzyme DPP-4, typically within two to three minutes of release.

GLP-1 receptor agonist medications are engineered to resist this rapid breakdown, allowing them to remain active in the body for days rather than minutes. This extended activity amplifies the hormone's natural appetite-suppressing and blood-sugar-regulating effects far beyond what the body achieves on its own.

How GLP-1 Medications Produce Weight Loss

The weight loss effects of GLP-1 medications stem from multiple simultaneous mechanisms:

  • Appetite reduction: GLP-1 receptor agonists act on receptors in the hypothalamus and brainstem, reducing the subjective experience of hunger and increasing feelings of fullness after smaller meals.
  • Delayed gastric emptying: By slowing the rate at which food moves from the stomach into the small intestine, these medications extend the period of post-meal satisfaction.
  • Reward pathway modulation: Emerging research suggests GLP-1 receptor agonists may reduce the rewarding properties of highly palatable foods, effectively dampening cravings for calorie-dense options.

Clinical Evidence and Efficacy

The clinical data supporting GLP-1 medications for weight management is substantial. The landmark STEP 1 trial, published in the New England Journal of Medicine (Wilding et al., 2021), found that participants receiving 2.4 mg of semaglutide weekly lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% in the placebo group. This represented one of the largest weight reductions ever achieved through pharmaceutical intervention in a clinical trial setting.

The SURMOUNT-1 trial, published in the New England Journal of Medicine (Jastreboff et al., 2022), demonstrated even more pronounced results for tirzepatide — a dual GIP/GLP-1 receptor agonist. Participants on the highest dose (15 mg) achieved an average weight loss of 22.5% over 72 weeks. Approximately 63% of participants on this dose lost more than 20% of their body weight.

According to data compiled by the American Journal of Managed Care (2023), prescriptions for GLP-1 receptor agonists increased by over 300% between 2020 and 2023, reflecting both expanded FDA approvals for weight management indications and growing public awareness of these treatments.

Common Side Effects and Considerations

While GLP-1 medications have demonstrated remarkable efficacy, they are not without limitations. The most frequently reported side effects are gastrointestinal in nature:

  • Nausea (reported in 20-44% of participants across major trials)
  • Vomiting, diarrhea, and constipation
  • Abdominal pain and bloating

These side effects are typically most pronounced during the dose-escalation phase and tend to diminish over time. More serious but rare concerns include pancreatitis, gallbladder disease, and potential thyroid C-cell tumor risk (observed in rodent studies). GLP-1 medications are contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

A significant clinical concern is weight regain after discontinuation. A study published in Diabetes, Obesity and Metabolism (Wilding et al., 2022) found that participants regained approximately two-thirds of their lost weight within one year of stopping semaglutide, underscoring the importance of sustainable lifestyle strategies alongside pharmaceutical approaches.

The Accessibility Challenge

Despite their effectiveness, GLP-1 medications remain inaccessible to many individuals due to cost and supply constraints. Without insurance coverage, monthly costs can exceed,000 in the United States. Supply shortages have been reported by the FDA intermittently since 2022. These barriers mean that for many people, building a foundation of healthy eating habits, regular physical activity, and evidence-based supplementation remains the primary path to managing appetite and body weight.

Natural Approaches to GLP-1 Support

Research is ongoing into natural compounds that may support the body's own GLP-1 production or enhance receptor sensitivity. Dietary strategies including increased fiber intake, consuming fermented foods, and prioritizing protein at meals have all shown modest effects on endogenous GLP-1 levels. Certain botanical extracts, including African mango extract and berberine, are under investigation for their potential to complement appetite-regulation pathways naturally.

For individuals who do not have access to prescription GLP-1 medications or prefer a natural approach, supplements like S&J Kraving Killa™ by S&J Luxury Fitness offer a formulation designed to support appetite management through complementary botanical and nutritional ingredients.

Related Topics